Tarsus Pharmaceuticals’ (TARS) “Buy” Rating Reiterated at HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Tuesday, TipRanks reports. They currently have a $40.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 201.66% from the stock’s current price.

Several other research firms have also recently commented on TARS. Zacks Investment Research raised Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 24th. Oppenheimer raised their target price on Tarsus Pharmaceuticals from $55.00 to $66.00 in a research note on Monday. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $48.00.

TARS traded down $0.74 on Tuesday, hitting $13.26. 17,633 shares of the company’s stock were exchanged, compared to its average volume of 37,710. Tarsus Pharmaceuticals has a fifty-two week low of $13.49 and a fifty-two week high of $39.08. The company has a market capitalization of $274.61 million, a PE ratio of -18.32 and a beta of 1.44. The firm’s 50-day simple moving average is $17.94.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last posted its quarterly earnings results on Monday, March 14th. The company reported ($0.72) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.05. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $7.11 million. Tarsus Pharmaceuticals had a negative net margin of 24.25% and a negative return on equity of 7.66%. As a group, equities analysts anticipate that Tarsus Pharmaceuticals will post -4.02 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 1.7% during the 4th quarter. BlackRock Inc. now owns 448,958 shares of the company’s stock worth $10,101,000 after purchasing an additional 7,338 shares during the period. Goldman Sachs Group Inc. boosted its stake in Tarsus Pharmaceuticals by 6.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 28,103 shares of the company’s stock worth $632,000 after buying an additional 1,623 shares during the period. State Street Corp increased its position in shares of Tarsus Pharmaceuticals by 2.3% during the fourth quarter. State Street Corp now owns 129,742 shares of the company’s stock valued at $2,919,000 after acquiring an additional 2,940 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 125,815 shares of the company’s stock valued at $2,830,000 after acquiring an additional 2,117 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Tarsus Pharmaceuticals by 21.2% in the 4th quarter. Ensign Peak Advisors Inc now owns 242,451 shares of the company’s stock valued at $5,456,000 after acquiring an additional 42,451 shares during the period. Institutional investors own 70.00% of the company’s stock.

About Tarsus Pharmaceuticals (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Further Reading

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.